Clinical Trial Matcher

Condition

Crohn's Disease clinical trials

Recruiting and not-yet-recruiting Crohn's Disease studies, refreshed daily. Want them ranked for you? Paste your diagnosis, treatments, and location and the matcher checks ClinicalTrials.gov, EU, WHO, and ISRCTN registries for studies that fit.

Match Crohn's Disease trials to my notes

791 studies matched on ClinicalTrials.gov for the query below. Retrieved November 7, 2026. This page does not say who can enroll.

Query

Crohns Disease OR Inflammatory Bowel Disease

Names the matcher also recognizes: Crohn's Disease, Inflammatory Bowel Disease, IBD. Abbreviations shorter than five letters stay off the query so a string such as MS does not pull unrelated records. Status filter: recruiting or not yet recruiting. The same names are how a personalized search starts. Washout timing still needs the treatment end date you enter on the search form. Read how matching works before treating any line below as a fit.

Studies in this retrieval

  1. NCT06715540

    Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects

    Recruiting · Phase 1 · registry updated 2024-12-16

    The goal of this clinical trial is to investigate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of BCD-261 after single subcutaneous injection at ascending doses and proposed therapeutic doses to healthy male subjects aged from 18 to 45 years old. The study consists of the first stage (dose escalation) and the second stage (dose expansion).

  2. NCT07143188

    The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares

    Not Yet Recruiting · Not Applicable · registry updated 2026-09-28

    Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic inflammatory conditions of the gastrointestinal tract that affect millions of people in the United States of America. Among patients with IBD, symptomatic flares are quite common; up to 40-50% of patients in some populations report having a flare at least once per month. For most patients with IBD flares, the typical outpatient treatment consists of corticosteroids and, in some instances, initiation of or switching between 5-aminosalicylic acid-acid preparations, immunomodulators, or biologics. These treatments, while often effective, can have harmful side effects, especially when used for long durations of time. Therefore, alternative treatments are highly sought after by both patients and providers.

  3. NCT06720961

    The Microbial Impact on Intestinal Fibrosis and the Associated Immune Microenvironment in Crohn's Disease

    Not Yet Recruiting · Not specified · registry updated 2025-02-14

    The goal of this study is to find out if there is a direct connection between an imbalance of gut bacteria and the development of scar tissue in the gut by identifying important bacterial proteins found in scarred gut tissue. Our aim is to identify which types of cells and biological processes are affected by these bacterial proteins in people with Crohn's Disease. We will also study how these bacterial proteins cause changes in 3D models of gut fibrosis.

  4. NCT06992453

    Multi-omics Dissection of Gut Microbiome Engraftment During FMT

    Recruiting · Not Applicable · registry updated 2026-10-26

    The gut microbiota plays a key role in immunity and metabolism and contributes to diseases such as recurrent C. difficile infection (rCDI), ulcerative colitis (UC), and metabolic syndrome (MetS). Microbiota therapeutics, particularly fecal microbiota transplantation (FMT), show promise-achieving \~90% cure rates in rCDI-but demonstrate variable efficacy in chronic conditions. Microbiome engraftment appears critical for FMT success, yet consistent predictors remain lacking. A meta-analysis of 20 FMT studies by our group and the Segata Lab linked engraftment to clinical response across diseases, with taxon-specific patterns and ML-based predictability. While viral, fungal, host immune, genetic, and metabolic factors may affect engraftment, their roles are not well-defined. Key unresolved questions include the interplay among host factors, microbial strains, and metabolites, their influence on engraftment, and impact on clinical outcomes. This study aims to unravel microbiome engraftment dynamics and link them to therapeutic response.

  5. NCT07292454

    Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe

    Not Yet Recruiting · Not specified · registry updated 2025-12-18

    Clinical and experimental data suggest that dysbiosis may play a pivotal role in the pathogenesis of intestinal bowel disease (IBD). However, to the best of our knowledge, the composition of gastric and of intestinal microbiome has never been investigated in a population with IBD according to the presence/absence of Helicobacter pylori (H. pylori) in the stomach.

  6. NCT06595719

    Multi-Strain Probiotics Supplementation With Standard Care in Mild to Moderate Ulcerative Colitis

    Recruiting · Not Applicable · registry updated 2025-03-12

    Probiotics are one of the adjunctive treatments that have been extensively explored for Ulcerative colitis (UC) disease management. Probiotics, a group of beneficial bacteria, can bring various health benefits when adequately supplied to the body, especially for gut wellness. In particular, for UC patients, gut dysbiosis is one of the contributing factors in their pathogenesis. Thus, the supplementation of probiotics in combination with standard treatment can potentially help in relieving symptoms as well as promoting mucosal healing for long-term remission.

  7. NCT07389161

    Uneven Nutrition and Life Style as IBD Triggers in Adolescents and Adults

    Recruiting · Not Applicable · registry updated 2026-04-29

    The aims of the study are 1. to determine the effect on dysbiosis, permeability and inflammatory activity after administration of a Mediterranean like diet (a Nordic equivalent, "Nordiet"), 2. to investigate life style related factors, such as exercise, psychosexual health and quality of life and their relation to the disease activity.

  8. NCT04314375

    Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

    Recruiting · Phase 4 · registry updated 2025-09-16

    This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects, with active, mild to moderate ulcerative colitis (UC). Subjects will be permitted to continue taking background oral or rectal 5-aminosalicylate (5-ASA) products.